You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Neurofibromatosis Type II

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Neurofibromatosis 1 Trial run by the National Cancer Institute (NCI) (Abemaciclib)

Recruiting
  • Neurofibromatosis 1
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 20, 2023

Neurofibromatosis 1 (NF1), Plexiform Neurofibromas (PN) Trial run by the NCI (Selumetinib)

Active, not recruiting
  • Neurofibromatosis 1 (NF1)
  • Plexiform Neurofibromas (PN)
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 31, 2023

Neurofibromatosis 1, Plexiform Neurofibromas Trial in Shanghai (HL-085)

Recruiting
  • Neurofibromatosis 1
  • Plexiform Neurofibromas
  • Shanghai, Shanghai, China
    Shanghai Ninth People's Hospital, Shanghai JiaoTong University S
Apr 10, 2022

Neurofibromatosis 1, Neurofibromatosis Type 1, NF1 Trial run by the National Cancer Institute (NCI) (AZD6244)

Active, not recruiting
  • Neurofibromatosis 1
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Aug 24, 2022

Neurofibromatosis Type 2, Vestibular Schwannomas Trial in New York (Axitinib)

Completed
Has Results
  • Neurofibromatosis Type 2
  • Vestibular Schwannomas
  • New York, New York
    NYU Langone Medical Center
Nov 24, 2021

Neurofibromatosis 1, Plexiform Neurofibroma, NF1 Trial in China, Spain, United States (FCN-159)

Recruiting
  • Neurofibromatosis 1
  • +2 more
  • Los Angeles, California
  • +11 more
Jul 25, 2022

NF1, Neurofibromatosis, Plexiform Neurofibromas Trial in United States (Cabozantinib)

Active, not recruiting
  • NF1
  • +2 more
  • Los Angeles, California
  • +11 more
Jan 13, 2023

Familial Investigations of Childhood Cancer Predisposition

Recruiting
  • Acute Leukemia
  • +45 more
    • Memphis, Tennessee
      St. Jude Children's Research Hospital
    May 11, 2022

    Neurofibromatosis Type 2, Neuroma, Acoustic Trial in Los Angeles (RAD001, everolimus)

    Active, not recruiting
    • Neurofibromatosis Type 2
    • Neuroma, Acoustic
    • RAD001, everolimus
    • Los Angeles, California
      University of California Los Angeles
    Mar 2, 2022

    Neurofibromatosis Type 1 Trial in Worldwide (Selumetinib granule formulation, Selumetinib capsule formulation)

    Recruiting
    • Neurofibromatosis Type 1
    • Selumetinib granule formulation
    • Selumetinib capsule formulation
    • Phoenix, Arizona
    • +17 more
    Aug 4, 2022

    Mitochondrial Dysfunction in Neurofibromatosis Type 1

    Not yet recruiting
    • Neurofibromatosis 1
    • Blood draw
    • FACIT-F and Pain Scales
    • (no location specified)
    Jun 12, 2023

    Neurofibromatosis 1 Trial in Boston (Kybella, Asclera)

    Recruiting
    • Neurofibromatosis 1
    • Boston, Massachusetts
      Wellman Center for Photomedicine
    Nov 1, 2023

    Neurofibromatosis Type 1, Plexiform Neurofibroma, Optic Nerve Glioma Trial in London (Selumetinib)

    Recruiting
    • Neurofibromatosis Type 1
    • +2 more
    • London, United Kingdom
    • +1 more
    Nov 11, 2021

    Neurofibromatosis 1 Trial in Boston (Deoxycholic Acid, Polidocanol, 1064nm Nd:YAG laser)

    Not yet recruiting
    • Neurofibromatosis 1
    • Deoxycholic Acid
    • +3 more
    • Boston, Massachusetts
      Wellman Center for Photomedicine
    Nov 13, 2023

    Neurofibromatosis 1, Plexiform Neurofibroma, NF1 Trial (Test group (Group A): FCN-159 8 mg, orally, once daily;, Control group

    Not yet recruiting
    • Neurofibromatosis 1
    • +2 more
    • Test group (Group A): FCN-159 8 mg, orally, once daily;
    • Control group (Group B): Placebo, orally, once daily;
    • (no location specified)
    Jun 16, 2023

    Disfigurement From Photographs of Neurofibromatosis Type 1

    Completed
    • Neurofibromatosis 1
      • Bethesda, Maryland
        National Institutes of Health Clinical Center
      Jan 20, 2023

      Natural History Study of Patients With Neurofibromatosis Type 2

      Recruiting
      • Neurofibromatosis
        • Bethesda, Maryland
          National Institutes of Health Clinical Center
        Jan 25, 2023

        Biology of Skin Neurofibromas in Neurofibromatosis Type 1

        Completed
        • Neurofibromatosis Type 1
        • Neurofibroma
          • Bethesda, Maryland
            National Institutes of Health Clinical Center
          Jan 20, 2023

          Low Grade Glioma (LGG) of Brain With BRAF Aberration, High Grade Glioma (HGG) of the Brain With BRAF Aberration, Low Grade

          Recruiting
          • Low Grade Glioma (LGG) of Brain With BRAF Aberration
          • +2 more
          • Phoenix, Arizona
          • +12 more
          Apr 7, 2022

          US Selumetinib Registry

          Not yet recruiting
          • Neurofibromatosis Type 1
          • Plexiform Neurofibromas
            • (no location specified)
            Jan 5, 2023

            Neurofibromatosis 1, Neurofibroma Plexiform Trial in Shanghai (Selumetinib)

            Active, not recruiting
            • Neurofibromatosis 1
            • Neurofibroma Plexiform
            • Shanghai, China
            • +1 more
            Jan 13, 2023

            Frameshift Peptides of Children With NF1

            Completed
            • Neurofibromatosis Type 1
            • Frameshift Array blood sample test
            • Washington, District of Columbia
            • +2 more
            Aug 29, 2022

            Neurofibromatosis 1, Neurofibroma, Plexiform Trial run by the NCI (Medication Event Monitoring System (MEMS))

            Active, not recruiting
            • Neurofibromatosis 1
            • Neurofibroma, Plexiform
            • Medication Event Monitoring System (MEMS)
            • Bethesda, Maryland
              National Institutes of Health Clinical Center
            Feb 2, 2023

            Development to Predict Malignant Conversion in Neurofibromatosis

            Recruiting
            • Neurofibromatosis 1
            • +2 more
            • Whole Body Magnetic Resonance Imaging
            • Baltimore, Maryland
              Johns Hopkins University
            Dec 22, 2022

            Neurofibromatosis Type 2 Trial in United States (REC-2282, Placebo)

            Recruiting
            • Neurofibromatosis Type 2
            • Los Angeles, California
            • +11 more
            Aug 5, 2022